Zydus Lifesciences secures USFDA approval to market its Scopolamine transdermal patch, targeting nausea and vomiting with a proven product in a growing $69.6 million market.(Wikimedia commons)  
Fitness and Wellness

Zydus Lifesciences Receives USFDA Approval for Scopolamine Transdermal System

New Approval Allows Zydus to Market Motion Sickness Treatment in the U.S.

Ankur Deka

New Delhi: Zydus Lifesciences Ltd announced on Friday that it has received final approval from the U.S. Food and Drug Administration (USFDA) to market its Scopolamine transdermal system, designed to prevent nausea and vomiting under various conditions.

The USFDA approval allows Zydus to market the Scopolamine transdermal system in a 1 mg/3 days dosage. The company stated in a regulatory filing that the product will be manufactured at its transdermal manufacturing facility at SEL, Matoda, Ahmedabad, Gujarat.

Zydus expands its transdermal portfolio with USFDA approval for the Scopolamine patch, a treatment designed for preventing nausea across multiple conditions. (Wikimedia commons)

The Scopolamine transdermal system is indicated for the prevention of nausea and vomiting associated with anesthesia, narcotic pain medications, and surgery. It is also used to prevent nausea and vomiting caused by motion sickness.

"This marks the fifth abbreviated new drug application (ANDA) approval for Zydus in its transdermal portfolio, showcasing the group's expertise in producing complex drug-device combinations," the company noted. According to data from IQVIA MAT for June 2024, the Scopolamine Transdermal System 1 mg/3 days had annual sales of USD 69.6 million in the U.S.

(Input from various sources)

(Rehash/Ankur Deka/MSM)

Also read:Introduction of Health Drinks by Zydus and Challenges in the Market

Also Read

Beyond Lavender Marriages: What Queer Unions and Relationships Can Teach us About Love and Safety

Beauty Sleep isn’t a Myth – A Sleep Medicine Expert Explains How Rest Keeps Your Skin Healthy and Youthful

When You’re Caught Between ‘Yes’ and ‘No,’ Here’s Why ‘Maybe’ Isn’t the Way to Go

Sophont, Founded by 22-Year-Old Innovator, Raises $9.22M Seed Round to Transform Healthcare with Multimodal AI

Doctor Arrested in Goa for Alleged Assault on Moroccan Patient in ICU